^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sEphB4-HSA

    i
    Other names: sEphB4-HSA, recombinant EphB4-HSA fusion protein, EphB4-HSA, EphB4-human serum albumin, human serum albumin-EphB4 conjugate, Vas 01
    Company:
    National Cancer Institute, VasGene
    Drug class:
    EphB4 inhibitor
    Related drugs:
    24d
    Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, University of Southern California | Terminated --> Active, not recruiting | Trial completion date: May 2019 --> Apr 2026
    Enrollment closed • Trial completion date
    |
    cisplatin • gemcitabine • docetaxel • albumin-bound paclitaxel • sEphB4-HSA
    6ms
    Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | N=170 --> 103
    Enrollment closed • Enrollment change
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    8ms
    sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=23, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025 | Trial primary completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    EPHB4 (EPH receptor B4)
    |
    sEphB4-HSA
    8ms
    sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, AIDS Malignancy Consortium | Trial completion date: Jun 2026 --> Feb 2026
    Trial completion date
    |
    EPHB4 (EPH receptor B4)
    |
    sEphB4-HSA
    8ms
    Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (clinicaltrials.gov)
    P2/3, N=700, Recruiting, Vasgene Therapeutics, Inc | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    EPHB4 (EPH receptor B4)
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv) • sEphB4-HSA
    10ms
    P30CA014089: Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (clinicaltrials.gov)
    P2, N=42, Completed, University of Southern California | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2024 | Trial primary completion date: Mar 2025 --> Sep 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    over1year
    Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. (PubMed, Oncotarget)
    The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC.
    Journal • PD(L)-1 Biomarker
    |
    EPHB4 (EPH receptor B4)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • sEphB4-HSA
    over1year
    Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (clinicaltrials.gov)
    P2/3, N=700, Not yet recruiting, Vasgene Therapeutics, Inc
    New P2/3 trial • IO biomarker
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Padcev (enfortumab vedotin-ejfv) • sEphB4-HSA
    over1year
    P30CA014089: Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, University of Southern California | Phase classification: P2a --> P2 | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    almost2years
    Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (clinicaltrials.gov)
    P2, N=170, Recruiting, University of Southern California | Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • sEphB4-HSA
    over2years
    sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, University of Southern California | N=36 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    sEphB4-HSA
    over2years
    sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, University of Southern California | Trial completion date: Apr 2025 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    sEphB4-HSA